Teva pharma to invest in India

Israel's Teva Pharmaceutical Industries, the world's largest manufacturer of copycat patented drugs (generics), plans to invest over $1 billion in India to acquire Indian drug companies and set up......

Indian pharma eyes US gains as $63.7 bn patent cliff nears

The Indian pharmaceutical industry is likely to benefit from a major wave of patent expiries in the US, as small-molecule drugs worth $63.7 billion are expected to go off-patent between 2025–29,......

Ranbaxy awaits US nod for generic drug

Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said it expected to get US approvals for a paediatric dosage of its generic version of Augmentin, GlaxoSmithKline's blockbuster antibiotic,......

Patent Office upholds Natco's plea

Drug maker Natco on Monday said that the Patent Office has upheld the firm's opposition to an application of Yeda Research & Development Company for patenting a generic version of a product of Teva......